Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Voyager Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing gene therapy and gene-modifying medicines for severe neurological diseases. The company operates within the biotechnology and pharmaceutical research industries, with a core emphasis on central nervous system (CNS) disorders. Voyager’s strategy centers on leveraging adeno-associated virus (AAV)–based gene delivery and capsid discovery technologies to enable targeted delivery of genetic payloads to specific brain regions and cell types.
Voyager’s primary value proposition lies in its TRACER™ AAV capsid discovery platform, which is designed to generate novel, proprietary AAV capsids with enhanced brain penetration and cell specificity. Founded in 2014 and originally incubated within the Broad Institute of MIT and Harvard, the company evolved from an internal research initiative into a publicly traded entity, completing its initial public offering in 2015. Since inception, Voyager has transitioned from early internal programs toward a partnership-driven model focused on advancing CNS gene therapies through both internal development and strategic collaborations.
Business Operations
Voyager operates through a single reportable segment focused on gene therapy research and development, generating revenue primarily from collaboration agreements, licensing arrangements, and research funding rather than product sales. The company’s internal pipeline targets neurological diseases such as Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions, with programs at preclinical and early clinical stages.
Operationally, Voyager’s core assets include its TRACER™ platform, proprietary AAV capsids, and associated intellectual property. The company conducts research primarily in the United States, with laboratory and corporate operations supporting discovery, preclinical development, and clinical-stage activities. Voyager has historically relied on strategic partnerships to offset development costs and accelerate clinical progress, while maintaining selective internal programs where it retains greater economic participation.
Strategic Position & Investments
Voyager’s strategic direction emphasizes platform expansion, capsid innovation, and selective pipeline advancement, positioning the company as a specialized CNS gene therapy partner to larger pharmaceutical firms. A central growth initiative is the continued refinement and application of its next-generation AAV capsids, particularly those designed for efficient blood–brain barrier crossing and targeted neuronal delivery.
The company’s most significant strategic collaboration is with Neurocrine Biosciences, which encompasses multiple CNS gene therapy programs, including candidates targeting Huntington’s disease and other neurological disorders. Voyager has also entered into and exited prior partnerships, including a former collaboration with Novartis, reflecting a shift toward more focused and capital-efficient alliances. Voyager does not operate a diversified investment portfolio; instead, its strategic investments are concentrated in internal R&D capabilities and partnered development programs leveraging its core technology platform.
Geographic Footprint
Voyager Therapeutics is headquartered in Cambridge, Massachusetts, within the United States, and conducts the majority of its research and corporate operations domestically. Its location places it within a major global biotechnology hub, providing access to academic collaborators, clinical research institutions, and industry talent.
While Voyager does not maintain large-scale international facilities, its global footprint is extended through strategic partnerships with multinational pharmaceutical companies. These collaborations provide indirect exposure to international clinical development, regulatory pathways, and potential commercialization activities across North America, Europe, and other major pharmaceutical markets, depending on partner-led trial and launch strategies.
Leadership & Governance
Voyager’s leadership team brings experience across biotechnology research, pharmaceutical development, and corporate strategy, with governance oversight aligned to public company standards. The company was co-founded by scientists and executives associated with the Broad Institute, reflecting its origins in academic translational research.
Key members of the executive leadership team include:
- Todd E. Carter – President & Chief Executive Officer
- Alfred W. Sandrock, Jr., M.D., Ph.D. – Chairman of the Board
- Matt Bielecki – Chief Financial Officer
- Arthur Tzianabos, Ph.D. – Chief Scientific Officer
The leadership philosophy emphasizes scientific rigor, disciplined capital allocation, and partnership-driven development, with a strategic vision focused on establishing Voyager as a leading innovator in CNS-targeted gene therapy technologies.